Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

acalabrutinib × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 109 Other hematologic neoplasm 61 Plasma cell 3 Gastrointestinal 2 Thoracic 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Classical hematology 1 CNS 1

Conditions

Carcinoma, Transitional Cell 1

Interventions

Docetaxel 408 pembrolizumab 330 Prednisone 289 enzalutamide 281 Gemcitabine 271 Radiotherapy 269 Magnetic Resonance Spectroscopy 266 Nivolumab 252 Abiraterone Acetate 217 Cisplatin 210 Leuprolide 195 Radiosurgery 191 Sunitinib 188 Carboplatin 162 Androgen Antagonists 153 bicalutamide 150 Goserelin 149 Specimen Handling 147 Ipilimumab 130 Paclitaxel 127 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122 apalutamide 117 Cyclophosphamide 117 Bevacizumab 116 Sorafenib 114 Everolimus 111 cabozantinib 104 atezolizumab 104 abiraterone 104 Biopsy 101

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02351739 2019-09-10

KEYNOTE143

Acerta Pharma BV

Phase 2 Completed

78 enrolled 10 charts

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡